Chang-Yi Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chang-Yi Lin has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Charles Jia-Yin Hou
Division of Cardiology, Department of Internal Medicine Mackay Memorial Hospital Taipei Taiwan
1 shared publication - Cheng-Ting Tsai
Cardiovascular Division, Department of Internal Medicine, MacKay Memorial Hospital, Taipei 104217, Taiwan
1 shared publication - Chung-Lieh Hung
Division of Cardiology, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan
1 shared publication - Heng-You Sung
Cardiovascular Division, Department of Internal Medicine, Mackay Memorial Hospital, No. 92, Sec. 2, Zhongshan N. Rd., Zhongshan Dist., Taipei, 251, Taiwan, 886 975835860
1 shared publication - Hung-I Yeh
Division of Preventive Cardiology and Pulmonary Circulation Medicine, Department of Cardiovascular Medicine/Cardiovascular Center, MacKay Memorial Hospital, Taipei, Taiwan
1 shared publication - Ying-Ju Chen
Telemedicine Center, MacKay Memorial Hospital, Taipei 10449, Taiwan
1 shared publication
Latest Publications
- Open Access
- 27 April 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (5) , 746
Personalized Management for Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical syndrome with multiple underlying mechanisms and comorbidities that leads to a variety of clinical phenotypes. The identification and characterization of these phenotypes are essential for better understanding the precise pathophysiology of HFpEF, identifying appropriate treatment strategies, and improving patient outcomes. Despite accumulating data showing the potentiality of artificial intelligence (AI)-based phenotyping using clinical, biomarker, and imaging information from multiple dimensions in HFpEF management, contemporary guidelines and consensus do not incorporate these in daily practice. In the future, further studies are required to authenticate and substantiate these findings in order to establish a more standardized approach for clinical implementation.
- 27 April 2023
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 13 (5) , 746
Open AccessPersonalized Management for Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a heterogeneous clinical syndrome with multiple underlying mechanisms and comorbidities that leads to a variety of clinical phenotypes. The identification and characterization of these phenotypes are essential for better understanding the precise pathophysiology of HFpEF, identifying appropriate treatment strategies, and improving patient outcomes. Despite accumulating data showing the potentiality of artificial intelligence (AI)-based phenotyping using clinical, biomarker, and imaging information from multiple dimensions in HFpEF management, contemporary guidelines and consensus do not incorporate these in daily practice. In the future, further studies are required to authenticate and substantiate these findings in order to establish a more standardized approach for clinical implementation.